MYSM1 and depressive symptom measurement: Immunohistochemical staining and the corresponding quantitative analysis data showed that, compared with those from patients without depression (Ctrl), there were more Mysm1 positive cells in the hippocampus, internal capsule, frontal lobe, and temporal lobe brain sections from patients with severe depression (MDD) (Figure 1F–J and Table 1).